Teva earmarks $1B for India

Here's more evidence that the developing world is hot, hot, hot. Teva Pharmaceutical Industries plans to invest a whopping $1 billion in India. The generics giant will spend between a quarter and a third of that on new manufacturing plants. The rest will go into acquisitions.

Teva recently bought 100 acres in Madhya Pradesh for new active pharmaceutical ingredient facilities. And banking sources told the Business Standard that Teva has been chasing major acquisitions on the subcontinent for three years. Possible targets: Indian drug makers Cipla, Aurobindo, Matrix, and Orchid.

"Teva considers India an interesting geographical region," a company spokeswoman told the local newspaper, "and is looking to broaden its activities in the country." Indeed.

- get the article in the Business Standard
- read this Pharmalot item

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.